Netherlands· NL-5715683ddbca

Darifenacine Aristo 7,5 mg tabletten met verlengde afgifte

A darifenacin product containing darifenacine hydrobromide, registered in Netherlands by Aristo Pharma GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC G04BD10

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about darifenacine hydrobromideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Darifenacin is registered in 15 of 19 countries.

Countries holding a registration under ATC G04BD10 (darifenacin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search darifenacin products by name

Darifenacin · ATC G04BD10

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Spainprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of darifenacin costs, country by country.

Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Darifenacin · price per daily dose (7.5 mg)

USD · FX 28 Sept 2026

CH Switzerland$1.84

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DARIFENACINE HYDROBROMIDE
Manufacturer: Aristo Pharma GmbH
Country: Netherlands (NL)
ATC code: G04BD10
ATC class: Darifenacin
Defined daily dose: 7.5 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
126979

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

246 interactions on record for darifenacin.

Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check darifenacin against other medicines How interaction checks work

Darifenacin · interactions on record

246 records

13 severe
155 moderate
1 minor
49 info

Most severe, free to view

Potassium chlorideA12BA01severe
Potassium citrateA12BA02severe
EliglustatA16AX10severe
Potassium chlorideB05XA01severe

28 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Darifenacin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All darifenacin products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

Germany · Darifenacin Aristo
Spain · Darifenacina Aristo
United Kingdom (Northern Ireland) · Darifenacin Aristo
Iceland · Emselex
Liechtenstein · Emselex
Norway · Emselex
Portugal · Darifenacina Aristo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/78c7bf85-61e3-44f8-9903-cb17033b3900
GET /v1/drugs/78c7bf85-61e3-44f8-9903-cb17033b3900?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet met verlengde afgifte",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h126979_smpc.pdf",
  "strength": null,
  "atc_label": "Darifenacin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg126979",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341)",
    "HYPROMELLOSE 2208 (Release controlling polymer), K4M (E 464)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "MACROGOL 4000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "DARIFENACINE HYDROBROMIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h126979.pdf",
  "authorised_at": "2021/05/10",
  "procedure_number": "NL/H/4424/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "126979",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about darifenacin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console